Anna Protopapas

Anna Protopapa is a veteran biotech entrepreneur with a substantial track record on building businesses from start-ups and growing them to become industry leaders in their respective categories. From 2015-2023 Anna served as President and Chief Executive Officer of Mersana Therapeutics, where she led the advancement of the company’s novel ADC platforms and pipeline, raised over $500mm in partnership and equity funding and transitioned the company to a publicly traded clinical-stage entity. Anna is currently the Chair of the Board of Directors of Nuvalent, an oncology focused biotech company and continues to serve on the Board of Directors for Mersana Therapeutics. Anna holds a B.S. in Science and Engineering from Princeton University, an M.S. in Chemical Engineering Practice from the Massachusetts Institute of Technology and an M.B.A. from Stanford Graduate School of Business.